SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs Q3 earnings report dominates discussion, with traders highlighting a strong beat and rapid growth in AI computing and Starlink. Bulls welcomed the results, while skeptics focused on heavy capital spending and the companys valuation; many were also surprised by the stocks muted, volatile reaction.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly results beat earnings expectations and met revenue estimates, but softer forward guidanceespecially a reduced advertising outlook and weaker next-quarter profit forecastsparked a selloff. Traders are split between viewing the reaction as an overreaction given stronger margins and buybacks, and seeing the outlook as evidence of slowing growth and execution concerns.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary Q1 update, with revenue and gross-margin estimates above prior guidance on AI-platform demand, is driving attention. Many traders welcomed the stronger outlook, while others questioned whether the gains would hold and cited lingering concerns about management credibility and the stocks volatility.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders await the 80th death event that triggers final analysis of its Phase 3 REGAL trial of GPS for AML, alongside upcoming SLS009 data. The sharp share-price rebound has fueled buyout and possible-news speculation, but others note there has been no confirmed catalyst and caution that the move may reflect trading volatility.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Q3 results beat expectations, but traders focused on slowing da Vinci procedure growth, an unchanged full-year outlook, and a one-time antitrust settlement charge. Bulls view the selloff as an overreaction and point to continued adoption, while bears cite decelerating growth and the stocks premium valuation.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile rebound after a sharp semiconductor selloff, as traders debate whether AI infrastructure spending can generate sufficient returns and whether debt risks at companies such as CoreWeave signal broader trouble. Bears see more downside if capex and financing concerns persist, while bulls view the pullback as overdone and expect upcoming earnings and guidance to reinforce AI-chip demand.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas upcoming Q3 earnings report is the main focus, with traders watching margins and updates on robotaxis and Optimus alongside the financial results. The recent rebound has drawn bullish calls and short-squeeze talk, while others view the run-up as a possible sell-the-news setup; SpaceX merger speculation is also circulating but remains unconfirmed.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Uniteds Q3 results and softer-than-expected Q4 outlook are driving discussion, with traders focused on rising fuel costs and pressure on airline margins. Some see resilient demand and revenue growth as positives, while others view the earnings shortfall and fuel burden as reasons for caution.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

The FAAs certification of Boeings 737 MAX 10 is the dominant topic, with traders debating whether the milestone can support a recovery. Many are frustrated that the shares showed little response or fell, arguing that certification alone does not resolve production and delivery constraints or uncertainty about cash flow; others view it as an important step toward converting the order backlog into deliveries.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A rebound after a sharp AI-neocloud selloff has traders debating whether the move signals stabilization or is only a temporary bounce. Financing costs and concerns about the sectors viabilityamplified by CoreWeaves debt worries and Gartners warningare weighed against bulls view that Nebius is better positioned, with earnings expected to provide more clarity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now

BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.

AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results

ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.

Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide

Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide

 US futures are flat, with S&P contracts clinging to small gains and the Nasdaq slipping into the red as memory stocks slide, after a weekend of contradictory geopolitical headlines whipsawed oil...

BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300

Equity

According to The Fly, JPMorgan sees a potential market opportunity of more than $2 billion for Biogen’s felzartamab in antibody-mediated rejection.


Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet...

Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?

AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?

Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Neutral Sentiment

<ul class="summary-bullets"><li>JPMorgan highlighted litifilimab’s development for cutaneous lupus erythematosus, a condition with no currently approved targeted therapies.</li><li>Last week, UBS raised its Biogen price target to $270 from $240 while maintaining 'Buy', while RBC Capital lowered its target to $256 from $260 and maintained 'Outperform', according to The Fly.</li><li>Biogen is scheduled to report its third-quarter 2026 results on October 28, with analysts expecting earnings of $2.66 per share and revenue of approximately $2.65 billion, according to FiscalAI.&nbsp;</li></ul><p>Shares of Biogen(BIIB) were in focus on Monday after JPMorgan upgraded the stock to an ‘Overweight’ rating from ‘Neutral’ rating and raised its price target to $300 from $210.</p><p>According to The Fly, the firm cited an increasingly compelling pipeline catalyst outlook and improved long-term growth prospects as the company approaches several clinical readouts in 2027.</p><p><a href="https://stocktwits.com/symbol/BIIB">Biogen shares</a> were trading 3.2% higher in premarket trading on Monday at $232.95, putting the stock on track to reach its highest level since July 2024, a more than two-year high.</p><h2 class="st-heading-2">What Are The Clinical Catalysts To Watch?</h2><p>JPMorgan highlighted two investigational treatments in Biogen's pipeline: felzartamab for antibody-mediated rejection and litifilimab for cutaneous lupus erythematosus. The firm identified felzartamab as a potential opportunity worth more than $2 billion and noted that no therapies are currently approved for cutaneous lupus erythematosus, according to The Fly.</p><p>Biogen's second-quarter 2026 materials listed Phase 3 readouts for both programs among the clinical milestones expected in 2027.</p><h2 class="st-heading-2">Why JPMorgan Mentioned Leqembi</h2><p>Leqembi is Biogen's Alzheimer's disease treatment, developed in collaboration with Eisai. Biogen reported global in-market sales of $184 million for Leqembi in the second quarter of 2026, up 15% year over year. U.S. in-market sales were $97 million.&nbsp;</p><p>JPMorgan said Biogen was evolving beyond “just a Leqembi story,” referring to the company's broader business and pipeline in its assessment of the stock.</p><h2 class="st-heading-2">What Have Other Analysts Said?</h2><p>JPMorgan’s upgrade follows price-target adjustments from UBS and RBC Capital last week, according to The Fly.</p><p>On Friday, October 9, UBS raised its price target on Biogen to $270 from $240 while maintaining a Buy rating. The adjustment came as part of the firm's Q3 earnings preview for U.S. pharmaceutical and large-cap biotech companies, according to The Fly.</p><p>On Thursday, October 8, RBC Capital lowered its price target to $256 from $260 while maintaining an Outperform rating. In its broader biotech earnings preview, RBC said the quarter was shaping up reasonably well for large-cap companies, helped partly by additional selling days and mid-year price increases.</p><p>RBC added that quarterly performance alone might not fully reverse sentiment toward commercial mid-cap biotech companies, although it “may help restore confidence in select stories,” according to The Fly.</p><h2 class="st-heading-2">When Is Biogen Reporting Q3 2026 Earnings?</h2><p>Biogen is scheduled to report its third-quarter 2026 financial results on Wednesday, October 28, before the market opens.</p><p>Analysts expect earnings of $2.66 per share and revenue of approximately $2.65 billion, according to FiscalAI.&nbsp;</p><h2 class="st-heading-2">How Retail Views BIIB?</h2><p>Retail sentiment on Stocktwits remained ‘neutral,’ while message volume was ‘high’ over the past 24 hours.</p><p>Biogen shares have gained more than 27% year-to-date.</p><p><strong>Also read: </strong><a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bmnr-stock-gains-with-ethereum-outpacing-bitcoin-after-84-k-bounce/cZxIe9tRBFw"><strong>BMNR Stock Gains With Ethereum Outpacing Bitcoin After $84K Bounce Ahead Of CPI Report This Week</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Medical bottles and syringe are seen with Biogen logo displayed on a screen in the background in this illustration photo taken in Krakow, Poland on November 10, 2022. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Shares of Biogen(BIIB) were in focus on Monday after JPMorgan upgraded the stock to an ‘Overweight’ rating from ‘Neutral’ rating and raised its price target to $300 from $210.

Biogen Is More Than ‘A Leqembi Story,’ Says Analyst – Flags Two Other Drug Candidates That Could Change Its Growth Story

Track BIIB stock price, charts, news and real-time market activity on Stocktwits. Join the BIIB message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Biogen Inc stock.

BIIB Stock Price Today - Biogen Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$243.10
Prev Close	$233.48
Open	$236.79
Dividend Yield	0.00%
50-Day Moving Average	$220.22
Beta	0.57
Avg. Volume	1.02M
PE Ratio	41.35

52-Week High	$240.99
52-Week Low	$138.00
Market Capitalization	$34.5B
EPS (Annual)	$8.79
Price to Book	1.83
Revenue Per Employee	$1.27M

Feed

News

Sentiment

Earnings

Fundamentals

Info

BIIB Fundamentals